Table 2.
Phase III studies of combined regimen with EGFR-TKI as the first-line treatment for EGFR-mutated NSCLC
| Name of studyreference (number of patients) | Combined regimen Compared treatment | RR (%) | PFS (m) | HR (95%CI) p value | OS (m) | HR (95%CI) p value |
|---|---|---|---|---|---|---|
| EGFR-TKI combined with cytotoxic agents | ||||||
| NEJ00927) (n = 345) | gefitinib+CBDCA+PEM | 71 | 20.9 | 0.49 (0.39–0.62) | 50.9 | 0.72 (0.55–0.95) |
| gefitinib | 47 | 11.2 | <0.001 | 38.8 | 0.021 | |
| Noronha’s study28) (n = 350) | gefitinib+CBDCA+PEM | 74 | 16 | 0.51 (0.39–0.66) | NR | 0.45 (0.31–0.65) |
| gefitinib | 31 | 8 | <0.0001 | 17 | <0.0001 | |
| EGFR-TKI combined with anti-angiogenic agent | ||||||
| NEJ02630) (n = 228) | erlotinib+bevacizumab | 61 | 16.9 | 0.605 (0.417–0.877) | 28.2 | 0.88 |
| erlotinib | 22 | 13.3 | 0.016 | 28.2 | 0.385 | |
| RELAY31) (n = 449) | erlotinib+ramucirumab | 74 | 19.4 | 0.591 (0.461–0.760) | NR | 0.83 (0.53–1.30) |
| erlotinib | 31 | 12.4 | <0.0001 | NR | NA | |
RR, response rate; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; CBDCA, carboplatin; PEM, pemetrexed; NR, not reached; NA, not available.